U
TCRT icon

UBS’s Alaunos Therapeutics TCRT Stock Holding History

UBS’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$667K Sell
1,686
-503
-23% -$242K ﹤0.01% 4003
2014
Q2 		$1.32M Buy
2,189
+329
+18% +$183K ﹤0.01% 3290
2014
Q1 		$1.28M Sell
1,860
-888
-32% -$595K ﹤0.01% 3241
2013
Q4 		$1.79M Buy
2,748
+781
+40% +$465K ﹤0.01% 2916
2013
Q3 		$1.16M Buy
1,967
+1,672
+567% +$753K ﹤0.01% 3178
2013
Q2 		$94K Buy
+295
New +$81.9K ﹤0.01% 5986

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS's TCRT Position: Q3 2014 in Review

UBS reduced its Alaunos Therapeutics (TCRT) stake by 23% in Q3 2014, selling an estimated $242K and leaving 1,686 shares worth $667K. The position accounts for ﹤0.01% of the portfolio, ranked #4003.

UBS first reported a position in TCRT in Q2 2013 and has held it in 6 quarters since. The position peaked at $1.79M in Q4 2013. 94 funds tracked by Wall St. Rank hold TCRT as of Q3 2014.

  • UBS held 1,686 shares of Alaunos Therapeutics worth $667K as of Q3 2014.
  • UBS sold 503 Alaunos Therapeutics shares in Q3 2014, an estimated $242K.
  • Alaunos Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4003 holding.
  • UBS first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 6 quarters since.
  • UBS's Alaunos Therapeutics position peaked at $1.79M in Q4 2013.
  • 94 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.